This paper deals with the topic of related R&D and innovation strategies of large firms. We ask what determines the diversity of a firm's product portfolio. More specifically, we try to explain large firms' expansion into new product markets driven by the characteristics of their technological...

Quelles sont les causes de l’appropriation des ressources végétales et ses conséquences sur le développement économique ? La constitution du potentiel d’innovation des firmes multinationales est si coûteuse que l’appropriation des inventions qui en découlent, mais aussi des...

This paper investigates the institutional and organizational sources of change and persistence in the technological systems which bring new products to market in the Chinese pharmaceutical industry. Even after fifteen years of economic reforms, research institutes, manufacturers and wholesalers...

Does a firm engage in a joint venture with a technologically advanced foreign partner to complement or substitute investments in its own technological capabilities? We address this question in a comparative study of 222 Chinese pharmaceutical manufacturers and Sino-foreign joint ventures. A...

This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Porject-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase lengths and failure rates are used to determine estimates of the R&D...

Academic institutions, involved in technology transfer to industry, are always concerned about the "fairness" of the royalty rate payable to them. The common method used by practitioners is the "Industry-Standard Approach" which is based mainly on past experience. However such approach is very...

Au-delà de ses fonctions en termes de protection et de financement de l’innovation, le brevet est aussi un instrument de médiation et un support d’interactions. Dans le cas du développement des nouveaux vaccins issus du génie génétique, nous montrons qu’il est une composante...